EMA’s Committee To Assess Further Data On Risk Of Heart Inflammation With mRNA COVID-19 Vaccines
EMA’s safety committee is assessing further data on the risk of myocarditis and pericarditis after vaccination with COVID-19 shots from Pfizer…
Moderna Announces First Participant Dosed In Phase 3 Pivotal Registration Study OIf Its mRNA Cytomegalovirus (CMV) Vaccine
CMV is the most common infectious cause of birth defects in the U.S.; there is no approved vaccine to prevent CMV
CMV is a latent virus that remains in the body for life after infection and can lead to lifelong medical
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech’s Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours:
Moderna Press Release Confirms European Medicines Agency’s CHMP Recommended Co.’s Booster Dose For COVID-19 Vaccine In European Union
Recommendation granted for individuals 18 years of age and older
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today
Why Moderna Shares Are Rising
Moderna Inc (NASDAQ: MRNA) shares are trading higher after the company reported results from a study in children 6-11 years of age and announced the primary immunogenicity endpoints were met.
According to the press release: